David P Rosenbaum (David Rosenbaum)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 12

Top Venues

Current medical research and opinion

Clinical drug investigation

British journal of clinical pharmacology

Journal of clinical pharmacology

Ardelyx, Inc.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Ardelyx, Inc.

United States

Chief Development Officer

Publications

Stuart M Sprague, Susan Edelstein, David M Spiegel, David P Rosenbaum, Cher Thomas, Daniel E Weiner
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study. Current medical research and opinion 40 (8) (2024)
Stuart M Sprague, Susan Edelstein, David M Spiegel, David P Rosenbaum, Cher Thomas, Daniel E Weiner
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study. Current medical research and opinion (2024)
Arnold Silva, Susan Edelstein, Yang Yang, David P Rosenbaum, Lori Battelli, Glenn M Chertow
Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study. Current medical research and opinion 40 (8) (2024)
Stuart M Sprague, Susan Edelstein, David M Spiegel, David P Rosenbaum, Cher Thomas, Daniel E Weiner
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study. Current medical research and opinion 40 (8) (2024)
Stuart M Sprague, Susan Edelstein, David M Spiegel, David P Rosenbaum, Cher Thomas, Daniel E Weiner
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study. Current medical research and opinion (2024)
Anthony J Lembo, Susan Edelstein, David P Rosenbaum, Ceciel Rooker, Jeffrey D Roberts, William D Chey
Long-term safety of tenapanor in people with irritable bowel syndrome with constipation from the T3MPO-3 study: plain language summary of publication. Therapeutic advances in gastroenterology 17 (2024)
Arnold Silva, Susan Edelstein, Yang Yang, David P Rosenbaum, Lori Battelli, Glenn M Chertow
Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study. Current medical research and opinion 40 (8) (2024)
Arnold Silva, Susan Edelstein, Yang Yang, David P Rosenbaum, Lori Battelli, Glenn M Chertow
Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study. Current medical research and opinion (2024)
Andrew J King, Matthew Siegel, Ying He, Baoming Nie, Ji Wang, Samantha Koo-McCoy, Natali A Minassian, Qumber Jafri, Deng Pan, Jill Kohler, Padmapriya Kumaraswamy, Kenji Kozuka, Jason G Lewis, Dean Dragoli, David P Rosenbaum, Debbie O'Neill, Allein Plain, Peter J Greasley, Ann-Cathrine Jönsson-Rylander, Daniel Karlsson, Margareta Behrendt, Maria Strömstedt, Tina Ryden-Bergsten, Thomas Knöpfel, Eva M Pastor Arroyo, Nati Hernando, Joanne Marks, Mark Donowitz, Carsten Alexander Wagner, Robert Todd Alexander, Jeremy S Caldwell
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Science translational medicine 10 (456) (2019)
David P Rosenbaum, Andrew Yan, Jeffrey W Jacobs
Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers. Clinical drug investigation 38 (4) (2018)
Bertram Pitt, Vanessa Zann, Chris Roe, Jeffrey W Jacobs, James P Davidson, Christine Dowd, Padmapriya Kumaraswamy, Fangling Lin, Paul Korner, Robert C Blanks, David P Rosenbaum
An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675. Journal of clinical pharmacology 58 (8) (2018)
Susanne Johansson, David P Rosenbaum, Johan Palm, Bergur Stefansson, Mikael Knutsson, Eleanor A Lisbon, Constanze Hilgendorf
Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers. British journal of clinical pharmacology 83 (9) (2017)

David P Rosenbaum.css-eqlu8i{font-size:small;padding-left:4px;} (David Rosenbaum)

Publication Activity (10 Years)

Top Topics

Top Venues

David P Rosenbaum (David Rosenbaum)